Severe adverse effects of 5-fluorouracil in S-1 were lessened by haemodialysis due to elimination of the drug

S-1 and cisplatin are used as one of the first-line chemotherapies for gastric cancer in Japan. The plasma concentration of 5-fluorouracil (5-FU) is increased in patients with renal dysfunction because gimeracil in S-1 inhibits the degradation of 5-FU and about 50% of gimeracil is excreted in the ur...

Descripción completa

Detalles Bibliográficos
Autores principales: Inoue, Kazunori, Nagasawa, Yasuyuki, Yamamoto, Ryohei, Omori, Hiroki, Kimura, Tomonori, Tomida, Kodo, Furumatsu, Yoshiyuki, Imai, Enyu, Isaka, Yoshitaka, Rakugi, Hiromi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2009
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421365/
https://www.ncbi.nlm.nih.gov/pubmed/25949315
http://dx.doi.org/10.1093/ndtplus/sfn195
Descripción
Sumario:S-1 and cisplatin are used as one of the first-line chemotherapies for gastric cancer in Japan. The plasma concentration of 5-fluorouracil (5-FU) is increased in patients with renal dysfunction because gimeracil in S-1 inhibits the degradation of 5-FU and about 50% of gimeracil is excreted in the urine. We describe a 35-year-old man with acute kidney injury while taking S-1 and cisplatin for advanced gastric cancer and who presented severe adverse effects of 5-FU. This case report describes the evolution of the plasma concentrations of 5-FU with haemodialysis along with a decrease in the adverse drug effects.

Ejemplares similares